Johnson & Johnson to buy Actelion for $30bn

ZURICH: US healthcare giant Johnson & Johnson will acquire Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.

Published January 26, 2017 Updated January 26, 2017 07:58am

3 min